A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of Frexalimab in Adult Patients With Primary Sjögren's Syndrome (phaethuSA)